DOP2021000066A - Compuestos, composiciones, y métodos para modular la actividad cdk9 - Google Patents

Compuestos, composiciones, y métodos para modular la actividad cdk9

Info

Publication number
DOP2021000066A
DOP2021000066A DO2021000066A DO2021000066A DOP2021000066A DO P2021000066 A DOP2021000066 A DO P2021000066A DO 2021000066 A DO2021000066 A DO 2021000066A DO 2021000066 A DO2021000066 A DO 2021000066A DO P2021000066 A DOP2021000066 A DO P2021000066A
Authority
DO
Dominican Republic
Prior art keywords
modulating
compositions
compounds
methods
cdk9 activity
Prior art date
Application number
DO2021000066A
Other languages
English (en)
Inventor
Mikochik Peter
Vacca Joseph
Freeman David
Tasker Andrew
Original Assignee
Kronos Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kronos Bio Inc filed Critical Kronos Bio Inc
Publication of DOP2021000066A publication Critical patent/DOP2021000066A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Inhibidores de CDK9 que son derivados de pirazolo [1,5-a] pirimidina y sus sales, correspondientes a la fórmula (I):
DO2021000066A 2018-10-30 2021-04-14 Compuestos, composiciones, y métodos para modular la actividad cdk9 DOP2021000066A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862752635P 2018-10-30 2018-10-30
US201962884993P 2019-08-09 2019-08-09
US201962910058P 2019-10-03 2019-10-03
PCT/US2019/058482 WO2020092314A1 (en) 2018-10-30 2019-10-29 Compounds, compositions, and methods for modulating cdk9 activity

Publications (1)

Publication Number Publication Date
DOP2021000066A true DOP2021000066A (es) 2021-10-31

Family

ID=70328627

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2021000066A DOP2021000066A (es) 2018-10-30 2021-04-14 Compuestos, composiciones, y métodos para modular la actividad cdk9

Country Status (20)

Country Link
US (3) US11155560B2 (es)
EP (1) EP3873911A4 (es)
JP (1) JP7385658B2 (es)
KR (1) KR20210068597A (es)
CN (1) CN112996790B (es)
AU (1) AU2019370200A1 (es)
BR (1) BR112021008176A2 (es)
CA (1) CA3118472A1 (es)
CO (1) CO2021005502A2 (es)
CR (1) CR20210202A (es)
DO (1) DOP2021000066A (es)
IL (1) IL282254A (es)
MA (1) MA54092A (es)
MD (1) MD20210033A2 (es)
MX (1) MX2021004769A (es)
PE (1) PE20212196A1 (es)
PH (1) PH12021550857A1 (es)
SG (1) SG11202104229WA (es)
WO (1) WO2020092314A1 (es)
ZA (1) ZA202102609B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11155560B2 (en) * 2018-10-30 2021-10-26 Kronos Bio, Inc. Substituted pyrazolo[1,5-a]pyrimidines for modulating CDK9 activity
WO2021216828A1 (en) * 2020-04-24 2021-10-28 Massachusetts Institute Of Technology Chimeric degraders of cyclin-dependent kinase 9 and uses thereof
JP2023548335A (ja) * 2020-11-05 2023-11-16 クロノス バイオ インコーポレイテッド Ｃｄｋ９活性を調節するための化合物および方法
CA3240110A1 (en) * 2021-11-24 2023-06-01 Kronos Bio, Inc. Polymorphic and salt forms of (1s,3s)-n1-(5-(pentan-3-yl)pyrazolo[1,5-a ]pyrimidin-7-yl)cyclopentane-1,3-diamine
WO2024017365A1 (zh) * 2022-07-22 2024-01-25 上海海雁医药科技有限公司 取代的吡唑并[1,5-a]嘧啶-7-胺衍生物的药学上可接受的盐和多晶型物及其应用

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5389632A (en) 1992-02-24 1995-02-14 Laboratoires Upsa Pyrazolopyrimidine derivatives which are angiotensin II receptor antagonists
ATE208776T1 (de) 1994-06-21 2001-11-15 Otsuka Pharma Co Ltd Pyrazolo(1,5-a) pyrimidin-derivate
CZ2005613A3 (cs) 1996-07-24 2017-01-25 Bristol-Myers Squibb Pharma Company Azolopyrimidiny, jejich použití a farmaceutické kompozice na jejich bázi
US20010007867A1 (en) 1999-12-13 2001-07-12 Yuhpyng L. Chen Substituted 6,5-hetero-bicyclic derivatives
WO2001023387A2 (en) 1999-09-30 2001-04-05 Neurogen Corporation CERTAIN ALKYLENE DIAMINE-SUBSTITUTED PYRAZOLO[1,5,-a]-1,5-PYRIMIDINES AND PYRAZOLO[1,5-a]-1,3,5-TRIAZINES
ATE347553T1 (de) 1999-09-30 2006-12-15 Neurogen Corp Amino-substituierte pyrazolo 1,5-aö-1,5- pyrimidine und pyrazolo 1,5-aö-1,3,5-triazine
JP2002308879A (ja) 2001-04-13 2002-10-23 Nippon Soda Co Ltd ５−ハロアルキル−アゾロピリミジン化合物、製造方法及び有害生物防除剤
AU2003227437A1 (en) 2002-04-23 2003-11-10 Shionogi And Co., Ltd. PYRAZOLO(1,5-a)PYRIMIDINE DERIVATIVE AND NAD(P)H OXIDASE INHIBITOR CONTAINING THE SAME
ATE365740T1 (de) 2002-05-10 2007-07-15 Smithkline Beecham Corp Substituierte pyrazolopyrimidine
MXPA04012245A (es) 2002-06-04 2005-09-30 Neogenesis Pharmaceuticals Inc Compuestos de pirazolo[1,5a]pirimidina como agentes antivirales.
US7605155B2 (en) * 2002-09-04 2009-10-20 Schering Corporation Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors
US7161003B1 (en) 2002-09-04 2007-01-09 Schering Corporation Pyrazolopyrimidines as cyclin dependent kinase inhibitors
US7205308B2 (en) 2002-09-04 2007-04-17 Schering Corporation Trisubstituted 7-aminopyrazolopyrimidines as cyclin dependent kinase inhibitors
US8580782B2 (en) 2002-09-04 2013-11-12 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors
US7563798B2 (en) 2002-09-04 2009-07-21 Schering Corporation Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors
JP4881558B2 (ja) 2002-09-04 2012-02-22 シェーリング コーポレイション サイクリン依存性キナーゼインヒビターとしてのピラゾロピリミジン
US7196078B2 (en) * 2002-09-04 2007-03-27 Schering Corpoartion Trisubstituted and tetrasubstituted pyrazolopyrimidines as cyclin dependent kinase inhibitors
AR041133A1 (es) 2002-09-04 2005-05-04 Pharmacopeia Drug Discovery Pirazolopirimidinas como inhibidores de la quinasa dependientes de la ciclina
US7119200B2 (en) 2002-09-04 2006-10-10 Schering Corporation Pyrazolopyrimidines as cyclin dependent kinase inhibitors
GB0305559D0 (en) 2003-03-11 2003-04-16 Teijin Ltd Compounds
US20070179161A1 (en) * 2003-03-31 2007-08-02 Vernalis (Cambridge) Limited. Pyrazolopyrimidine compounds and their use in medicine
US7501405B2 (en) 2003-04-11 2009-03-10 High Point Pharmaceuticals, Llc Combination therapy using an 11β-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent for the treatment of metabolic syndrome and related diseases and disorders
WO2004089471A2 (en) 2003-04-11 2004-10-21 Novo Nordisk A/S NEW PYRAZOLO[1,5-a] PYRIMIDINES DERIVATIVES AND PHARMACEUTICAL USE THEREOF
JP2005008581A (ja) 2003-06-20 2005-01-13 Kissei Pharmaceut Co Ltd 新規なピラゾロ［１，５−ａ］ピリミジン誘導体、それを含有する医薬組成物およびそれらの用途
US20070060595A1 (en) 2003-10-10 2007-03-15 Toshio Yoshizawa Novel fused heterocyclic compound and use thereof
US20070293511A1 (en) 2003-12-22 2007-12-20 Sb Pharmco Puerto Rico Inc. And Neurocrine Biosciences, Inc., A Corporation Crf Receptor Antagonists and Methods
US8018479B2 (en) 2008-08-27 2011-09-13 Lexmark International, Inc. Method and system for correcting the linearity error in electrophotographic devices
KR20070051325A (ko) 2004-08-13 2007-05-17 데이진 화-마 가부시키가이샤 피라졸로[1,5-ａ]피리미딘 유도체
CN101119998A (zh) 2004-12-21 2008-02-06 先灵公司 吡唑并[1,5－A]嘧啶腺苷A2a受体拮抗剂
DE102005007534A1 (de) 2005-02-17 2006-08-31 Bayer Cropscience Ag Pyrazolopyrimidine
AR057979A1 (es) 2005-10-06 2008-01-09 Schering Corp PIRAZOLPIRIMIDINAS COMO INHIBIDORAS DE PROTEíNA QUINASA. COMPOSICIONES FARMACEUTICAS.
TWI421078B (zh) 2005-10-06 2014-01-01 Merck Sharp & Dohme 關卡激酶抑制劑及其用途
US8188097B2 (en) 2005-10-21 2012-05-29 Mitsubishi Tanabe Pharma Corporation Pyrazolo[1,5-A]pyrimidine compounds
US7908091B2 (en) 2006-03-17 2011-03-15 Prometheus Laboratories Inc. Methods of predicting and monitoring tyrosine kinase inhibitor therapy
BRPI0712016A2 (pt) 2006-05-22 2011-12-27 Schering Corp pirazolo[1,5-a]pirimidinas
CA2688616A1 (en) 2007-06-05 2008-12-11 Emory University Selective inhibitors for cyclin-dependent kinases
US20100317607A1 (en) 2007-06-27 2010-12-16 Infectious Disease Research Institute Use of compounds for preparing anti-tuberculosis agents
CA2728559A1 (en) 2008-07-03 2010-01-07 Exelixis Inc. Cdk modulators
JP5578490B2 (ja) 2008-12-26 2014-08-27 味の素株式会社 ピラゾロピリミジン化合物
US8993612B2 (en) 2009-10-08 2015-03-31 Rhizen Pharmaceuticals Sa Modulators of calcium release-activated calcium channel and methods for treatment of non-small cell lung cancer
AU2010326268B2 (en) 2009-12-04 2016-11-03 Senhwa Biosciences, Inc. Pyrazolopyrimidines and related heterocycles as CK2 inhibitors
KR101478889B1 (ko) 2010-02-26 2015-01-02 미쓰비시 타나베 파마 코퍼레이션 피라졸로피리미딘 화합물 및 ｐｄｅ10 억제제로서의 그의 용도
CA2792102C (en) 2010-03-05 2015-06-09 Kyowa Hakko Kirin Co., Ltd. Pyrazolopyrimidine derivative
PE20130395A1 (es) 2010-06-24 2013-04-10 Gilead Sciences Inc Pirazolo[1,5-a]pirimidinas para tratamiento antiviral
JP5985473B2 (ja) 2010-07-13 2016-09-06 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ＩＲＡＫ４モジュレーターとしてのピラゾロ［１，５ａ］ピリミジン及びチエノ［３，２ｂ］ピリミジン誘導体
WO2012027236A1 (en) 2010-08-23 2012-03-01 Schering Corporation NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
US8957077B2 (en) 2010-09-30 2015-02-17 Merck Sharp & Dohme Corp. Pyrazolopyrimidine PDE 10 inhibitors
WO2012170827A2 (en) 2011-06-08 2012-12-13 Cylene Pharmaceuticals, Inc. Pyrazolopyrimidines and related heterocycles as ck2 inhibitors
CA2860724A1 (en) 2012-01-10 2013-07-18 Bayer Intellectual Property Gmbh Substituted pyrazolopyrimidines as akt kinase inhibitors
US9290500B2 (en) 2012-02-17 2016-03-22 Millennium Pharmaceuticals, Inc. Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzyme
WO2013130943A1 (en) 2012-03-02 2013-09-06 Genentech, Inc. Alkyl-and di-substituted amido-benzyl sulfonamide derivatives
JP6377068B2 (ja) 2012-11-16 2018-08-22 ユニバーシティ・ヘルス・ネットワーク ピラゾロピリミジン化合物
WO2014152518A2 (en) 2013-03-14 2014-09-25 Celtaxsys, Inc. Inhibitors of leukotriene a4 hydrolase
GB201403093D0 (en) 2014-02-21 2014-04-09 Cancer Rec Tech Ltd Therapeutic compounds and their use
US10844436B2 (en) 2014-04-01 2020-11-24 Cornell University Use of double-stranded DNA in exosomes: a novel biomarker in cancer detection
EP3129371B1 (en) 2014-04-05 2020-07-29 Syros Pharmaceuticals, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
ES2899196T3 (es) 2015-03-09 2022-03-10 Aurigene Discovery Tech Ltd Derivados de pirazolo[1,5-a][1,3,5]triazina y de pirazolo[1,5-a]pirimidina como inhibidores de CDK
US10550121B2 (en) 2015-03-27 2020-02-04 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
EP3286192A1 (en) 2015-04-20 2018-02-28 AbbVie Deutschland GmbH & Co KG Substituted pyrazolopyrimidines and method of use
AU2016276963C1 (en) 2015-06-12 2021-08-05 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
ES2767776T3 (es) 2015-10-01 2020-06-18 Bristol Myers Squibb Co Inhibidores de biaril cinasa
JP2018199623A (ja) 2015-10-22 2018-12-20 大正製薬株式会社 含窒素縮合複素環化合物
JP2019500328A (ja) 2015-11-19 2019-01-10 ブループリント メディシンズ コーポレイション Ｎｔｒｋに関連する障害の治療のために有用な化合物及び組成物
WO2017180499A2 (en) 2016-04-13 2017-10-19 President And Fellows Of Harvard College Methods for capturing, isolation, and targeting of circulating tumor cells and diagnostic and therapeutic applications thereof
US20190060296A1 (en) * 2017-07-28 2019-02-28 Massachusetts Institute Of Technology Discovery of small molecules that target the androgen receptor and uses
JP7216705B2 (ja) 2017-07-28 2023-02-02 ニンバス ラクシュミ， インコーポレイテッド Ｔｙｋ２阻害剤およびその使用方法
US11155560B2 (en) * 2018-10-30 2021-10-26 Kronos Bio, Inc. Substituted pyrazolo[1,5-a]pyrimidines for modulating CDK9 activity

Also Published As

Publication number Publication date
SG11202104229WA (en) 2021-05-28
CN112996790A (zh) 2021-06-18
WO2020092314A1 (en) 2020-05-07
MX2021004769A (es) 2021-08-24
US20240132506A1 (en) 2024-04-25
JP2022505268A (ja) 2022-01-14
US20200131189A1 (en) 2020-04-30
JP7385658B2 (ja) 2023-11-22
MD20210033A2 (ro) 2021-10-31
CN112996790B (zh) 2023-11-03
ZA202102609B (en) 2023-02-22
AU2019370200A1 (en) 2021-06-10
EP3873911A4 (en) 2022-06-22
CR20210202A (es) 2022-02-08
BR112021008176A2 (pt) 2021-08-03
CA3118472A1 (en) 2020-05-07
PE20212196A1 (es) 2021-11-16
US11155560B2 (en) 2021-10-26
MA54092A (fr) 2021-09-08
EP3873911A1 (en) 2021-09-08
US20220002305A1 (en) 2022-01-06
KR20210068597A (ko) 2021-06-09
PH12021550857A1 (en) 2021-12-06
IL282254A (en) 2021-05-31
US11845754B2 (en) 2023-12-19
CO2021005502A2 (es) 2021-09-20

Similar Documents

Publication Publication Date Title
DOP2021000066A (es) Compuestos, composiciones, y métodos para modular la actividad cdk9
CL2018001671A1 (es) Derivados de pirimidina 4-amino-2-(1h-pirazolo[3,4-b]piridina-3-yl)-6-oxo-6,7-dihidro-5h-pirrolo[2,3-d] y los derivados respectivos (1h-indazol-3-yl) como moduladores cgmp para el tratamiento de enfermedades cardiovasculares.
ECSP22052564A (es) Tetrahidrofuranos sustituidos como moduladores de canales de sodio
ECSP13013009A (es) INHIBIDORES DE QUINASA RELACIONADOS CON PIRROLO[2,3-d]PIRIMIDINA TROPOMIOSINA
UY32156A (es) Derivados sustituidos de la n2 - [1-(5 - fluoropirimidin -2-il) etil] - n4 - (1-metil - 1h-imidazol - 4 - il)) - pirimidina - 2,4 - diaminas y sus sales farmacéuticamente aceptables, proceso de preparación, composiciones conteniéndolos y aplicaciones.
UY37900A (es) Nuevos derivados de rapamicina
SV2009003216A (es) Nuevos derivados de 1, 4-benzotiepina 1, 1-dioxido sustituidos con radicales bencilo, metodo para su preparacion, productos farmaceuticos que comprenden estos compuestos, y su uso
PE20151501A1 (es) Inhibidores de prmt5 y sus usos
CR20130680A (es) Métodos plaguicidas que utilizan compuestos de 3-piridil tiazol sustituido y derivados para combatir las plagas de animales i
CR20120065A (es) COMPUESTOS DE PIRAZOLO[1,5-a]PIRIMIDINA SUSTITUIDOS COMO INHIBIDORES DE TRK-QUINASA
EA201890820A1 (ru) НОВЫЕ ПРОИЗВОДНЫЕ ПИРРОЛО[2,3-d]ПИРИМИДИНА В КАЧЕСТВЕ ДВОЙСТВЕННЫХ ИНГИБИТОРОВ DYRK1/CLK1
DOP2014000036A (es) Compuestos de piridazinona y su uso como inhibidores daao
UY28903A1 (es) Nuevos derivados de piridazinona
BR112021022536A2 (pt) Derivado de fenilpropenilpiridina substituída e método de preparação do mesmo e uso médico do mesmo
UY36713A (es) Triazoles para el tratamiento de enfermedades desmielinizantes
CO6470826A2 (es) Moduladores de lxr
UY31996A (es) Nuevos derivados de triazolo[4,3-a]piridina, y sus nuevos usos como inhibidores de met
CR20180323A (es) Derivados de indol n-sustituídos como moduladores de los receptores de pge2
DOP2018000062A (es) Piridinona dicaboxamidas para uso como inhibidores de bromodominio
UY31885A (es) Derivados de las 1, 3, 5-triazina-2, 4-diaminas-6-sustituidas-n-sustituidas y sales farmacéuticamente aceptables de los mismos, composiciones y aplicaciones.
GT200800285A (es) Aminopirazolopiridinas sustituidas y sus sales, sus preparaciones y composiciones farmaceuticas que las comprenden
NI201700129A (es) Azabenzimidazoles y su uso como moduladores del receptor ampa.
NI200900183A (es) Compuestos de pirido [2,3-d] pirimidina - 7 - ona como inhibidores de pi3k - alfa para el tratamiento del cáncer.
AR097545A1 (es) COMPUESTOS A BASE DE PIRAZOLO[1,5-a]PIRIMIDINA, COMPOSICIONES QUE LOS COMPRENDEN Y SUS MÉTODOS DE USO
CL2022000093A1 (es) Imidazopirimidinas como inhibidores de eed y uso de estas